, /PRNewswire/ -- (Nasdaq: ) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that , President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Cell Therapy Forum on at . An audio webcast of the event will be available on the Company's section of the Investor Relations webpage and will be archived for a limited time following the event. Carisma Therapeutics Inc.
is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in For more information, please visit .
Head of Investor Relations (763) 350-5223 SOURCE Carisma Therapeutics Inc..